BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
6 Well known Ladies' Fragrances On the planet - 2Careful Nurturing: Techniques for Bringing up Tough Children
- 3Figure out How to Explore the Infotainment Framework in the Slam 1500.
- 4Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- 5'It's doing badly': Fears grow for whale stuck off Germany's coast
- Doulas play essential roles in reproductive health care – and more states are beginning to recognize it
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- How Skoda Lost Its Biggest Market In Just Seven Years
- 10 Famous Frozen yogurt Flavors All over The Planet
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Millions in JDM Exports and Exotic Supercars Are Currently Trapped at Sea
- Pick Your Number one Sort Of Music
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
